- Oops!Something went wrong.Please try again later.
Eli Lilly And Co (NYSE: LLY) has reported posthoc analyses data from the Phase 3 RA-BEAM study that showed Olumiant 4mg (baricitinib) lowered pain and duration of morning joint stiffness in moderate to severe rheumatoid arthritis (RA) patients.
Discovered by Incyte Corporation (NASDAQ: INCY) and licensed to Lilly, Olumiant is an oral Janus kinase (JAK) inhibitor approved for treating moderately to severely active RA in adults.
Trial data showed that Olumiant also enhanced overall physical function at 12 weeks compared to adalimumab and placebo.
The changes in pain relief were not affected by disease activity during treatment, Lilly noted.
Furthermore, subjects receiving Olumiant had greater improvements in fatigue versus placebo, and the improvements were comparable to AbbVie Inc's (NYSE: ABBV) Humira after 12 weeks.
Price Action: LLY shares are up 0.47% at $199.35 during the market session on the last check Wednesday.
See more from Benzinga
© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.